Literature DB >> 29193860

Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity.

Agnes Szentpetery1, Gerard M Healy1, Darragh Brady1, Muhammad Haroon1, Phil Gallagher1, Ciaran E Redmond1, Hannah Fleming1, John Duignan1, Jonathan D Dodd1, Oliver FitzGerald2.   

Abstract

OBJECTIVE: To examine the effect of metabolic syndrome and psoriatic disease-related variables on coronary plaque burden in psoriatic arthritis (PsA) patients.
METHODS: Fifty PsA patients without symptoms of coronary artery disease (CAD) (25 with metabolic syndrome and 25 without metabolic syndrome) and 50 age- and sex-matched controls underwent 64-slice coronary computed tomography angiography. Plaque localization, segment involvement score (SIS), segment stenosis score (SSS), and total plaque volume (TPV) were calculated. Plaques were classified as calcified, mixed, or noncalcified. Kruskal-Wallis test, rank correlations, and linear regression analyses were used to study the relationship between PsA, metabolic syndrome, and plaque burden.
RESULTS: Plaques were found in 76% of PsA patients versus 44% of controls (P = 0.001), and a higher proportion of patients with PsA had affected coronary vessels (P = 0.007). SIS, SSS, and TPV were greater in PsA patients than controls (P = 0.003, P = 0.001, and P ≤ 0.001, respectively). More PsA patients had mixed plaques, and mixed plaque volume was higher than in controls (P < 0.001). PsA patients with metabolic syndrome and those without metabolic syndrome had similar plaque burdens and types. SIS, SSS, and TPV did not show significant relationships with features of metabolic syndrome, but did significantly correlate with disease activity measures. TPV was associated with a diagnosis of PsA (B = 0.865, P = 0.008), but not with metabolic syndrome. Age, highest C-reactive protein level, highest swollen joint count, disease duration, and plasma glucose level were independent predictors of higher plaque burden in PsA.
CONCLUSION: PsA is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease. Psoriatic disease activity and severity may predict coronary plaque burden better than traditional risk factors.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29193860     DOI: 10.1002/art.40389

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  11 in total

1.  Epicardial adipose tissue thickness in systemic sclerosis patients without overt cardiac disease.

Authors:  Duygu Temiz Karadag; Tayfun Sahin; Senem Tekeoglu; Ozlem Ozdemir Isik; Ayten Yazici; Ayse Cefle
Journal:  Rheumatol Int       Date:  2019-04-25       Impact factor: 2.631

Review 2.  Psoriatic arthritis from a mechanistic perspective.

Authors:  Georg Schett; Proton Rahman; Christopher Ritchlin; Iain B McInnes; Dirk Elewaut; Jose U Scher
Journal:  Nat Rev Rheumatol       Date:  2022-05-05       Impact factor: 20.543

Review 3.  Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.

Authors:  Sueli Carneiro; Penelope Esther Palominos; Sônia Maria Alvarenga Anti; Rodrigo Luppino Assad; Rafaela Silva Guimarães Gonçalves; Adriano Chiereghin; Andre Marun Lyrio; Antônio Carlos Ximenes; Carla Gonçalves Saad; Célio Roberto Gonçalves; Charles Lubianca Kohem; Cláudia Diniz Lopes Marques; Cláudia Goldenstein Schainberg; Eduardo de Souza Meirelles; Gustavo Gomes Resende; Lenise Brandao Pieruccetti; Mauro Waldemar Keiserman; Michel Alexandre Yazbek; Percival Degrava Sampaio-Barros; Ricardo da Cruz Lage; Rubens Bonfiglioli; Thauana Luíza Oliveira; Valderílio Feijó Azevedo; Washington Alves Bianchi; Wanderley Marques Bernardo; Ricardo Dos Santos Simões; Marcelo de Medeiros Pinheiro; Cristiano Barbosa Campanholo
Journal:  Adv Rheumatol       Date:  2021-11-24

Review 4.  Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?

Authors:  Fabiola Atzeni; Elisabetta Gerratana; Ignazio Francesco Masala; Sara Bongiovanni; Piercarlo Sarzi-Puttini; Javier Rodríguez-Carrio
Journal:  Front Med (Lausanne)       Date:  2021-08-30

Review 5.  Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease.

Authors:  Zhoulan Zheng; Qianyu Guo; Dan Ma; Xuexue Wang; Chengqiang Zhang; Haiyao Wang; Liyun Zhang; Gailian Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-06

Review 6.  T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.

Authors:  Fabio Casciano; Paolo D Pigatto; Paola Secchiero; Roberto Gambari; Eva Reali
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

Review 7.  Psoriatic arthritis and the association with cardiometabolic disease: a narrative review.

Authors:  Paras Karmacharya; Alexis Ogdie; Lihi Eder
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-02       Impact factor: 5.346

8.  Prevalence of high-risk coronary plaques in patients with and without metabolic syndrome and the relationship with prognosis.

Authors:  Xu Yang; Wei Luo; Shan Han; Lei Zha; Jing Zhang; Xiaowei Li; Hui Zhao; Shuo Liang; Ru Zhao
Journal:  BMC Cardiovasc Disord       Date:  2020-02-11       Impact factor: 2.298

9.  Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis.

Authors:  Isaac T Cheng; Ka Tak Wong; Edmund K Li; Priscilla C H Wong; Billy T Lai; Isaac C Yim; Shirley K Ying; Kitty Y Kwok; Martin Li; Tena K Li; Jack J Lee; Alex P Lee; Lai-Shan Tam
Journal:  RMD Open       Date:  2020-09

10.  Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.

Authors:  Laura Pina Vegas; Philippe Le Corvoisier; Laetitia Penso; Muriel Paul; Emilie Sbidian; Pascal Claudepierre
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.